Late cycle. Medicine ++In November 2023, it was reported that German chemical concern Bayer AG was considering options for splitting the business due to weak financial performance.
Management considered several options:
spinning off the health products or agricultural fertilizer businesses into a separate company;
Key facts today
On September 2, 2025, Bayer announced that Silchester International Investors LLP surpassed the 3% voting rights threshold as of August 29, 2025, per German Securities Trading Act.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.823 EUR
−2.67 B EUR
48.70 B EUR
3.93 B
About Bayer AG
Sector
Industry
CEO
William N. Anderson
Website
Headquarters
Leverkusen
Founded
1952
ISIN
US0727303028
FIGI
BBG000BMYJL6
Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
Related stocks
Bottom up with clear upside momentumXETR:BAYN Bayer is looking at a possible rebound after the stock rose strongly and attempting to break above the bearish gap seen.
Ichimoku is showing a strong bullish signal and we believe near-term should see further upside.
Long-term MACD is back to the positive. Stochastic confirms the bull
Bayer stock : Contrarian storyBayer stock might be considered a contrarian investment:
Legal overhang from Monsanto acquisition: The ongoing litigation related to the Roundup herbicide has created significant uncertainty and negatively impacted Bayer's stock price. A contrarian investor might see this as an overreaction and bel
Bayer AG Analysis: Growth Potential and Positive Buying SentimenThe history of Bayer AG shares goes through many key moments and events:
Foundation and early years: Bayer was founded in 1863 by Friedrich Bayer and Johann Wagner in Germany. The company initially dealt with the production of chemicals and textile dyes.
Development of aspirin: In 1897, Bayer synt
Bayer (BAYN): End of a long 9-year correctionBayer (BAYN): XETR:BAYN
Upon request from one of our members, we're taking a closer look at Bayer AG. We believe that we are still in an overarching Wave II. This wave finds its last true support at the 88.2% retracement level at €24.51. Falling significantly below this level would likely lead
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further.
The stock has held around the 88.2% Fibonacci retracement level. We
GERMANY STOCK > ( BAYN ) long Based on my graphic analysis I observe a bullish projection of 11% in the price of this corporation, that is; from $28.79 it will rise to $31.96. With a sell exit emerging at $26.47, it is worth remembering that exactly how long the rally will take is unpredictable, the market will simply do its job
Bayer double bottom Bayer was trending down for last almost a year. Now it's seems to draw the double botton. Stock found the support, bounce twice and seems to be recovering. Moreover, the dividend is incomingin near future what could boost the price additionally.
this is not a recomendation, only my guess what could
If Germany is the sick man of Europe. #Bayer looking deathlyThe #EU is Marxist, Socialist, and is involved in Price setting
That didn't work out too well for USSR as economic powerhouse
and so too we see the once great German economy being brought to it's knees.
It is being de-industralized and being brought down in a great economic levelling of the union
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BAYZ5705354
Bayer US Finance LLC 6.5% 21-NOV-2033Yield to maturity
—
Maturity date
Nov 21, 2033
BAYZ4646644
Bayer US Finance II LLC 4.25% 15-DEC-2025Yield to maturity
—
Maturity date
Dec 15, 2025
BAYZ4140709
Monsanto Company 4.2% 15-JUL-2034Yield to maturity
—
Maturity date
Jul 15, 2034
BAYZ3875861
Monsanto Company 3.6% 15-JUL-2042Yield to maturity
—
Maturity date
Jul 15, 2042
BAYZ4663164
Bayer US Finance II LLC 4.7% 15-JUL-2064Yield to maturity
—
Maturity date
Jul 15, 2064
BAYZ4790623
Bayer US Finance II LLC 5.875% 15-APR-2038Yield to maturity
—
Maturity date
Apr 15, 2038
BAYZ4646647
Bayer US Finance II LLC 4.875% 25-JUN-2048Yield to maturity
—
Maturity date
Jun 25, 2048
BAYZ4646646
Bayer US Finance II LLC 4.625% 25-JUN-2038Yield to maturity
—
Maturity date
Jun 25, 2038
BAYZ3949796
Conceptus, Inc. 5.0% 15-DEC-2031Yield to maturity
—
Maturity date
Dec 15, 2031
BAYZ5705348
Bayer US Finance LLC 6.125% 21-NOV-2026Yield to maturity
—
Maturity date
Nov 21, 2026
BAYZ4841297
Bayer US Finance II LLC 5.5% 30-JUL-2035Yield to maturity
—
Maturity date
Jul 30, 2035
See all BAYA bonds
Curated watchlists where BAYA is featured.

German Stocks: Continental champs
16 No. of Symbols
See all sparks